



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 6941

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/506,962	04/19/2005	514	1643	WEICKM-0041
RULE				
APPLICANTS Axel Ullrich, Muenchen, GERMANY; Beatrix Schaefer, Muenich, GERMANY; Oliver Fischer, Germering, GERMANY; Andreas Gschwind, Muenich, GERMANY; Michael Leserer, Germering, GERMANY;				
** CONTINUING DATA ***** This application is a 371 of PCT/JP03/02361 03/07/2003				
** FOREIGN APPLICATIONS ***** EUROPEAN PATENT OFFICE (EPO) 02005452.4 03/08/2002				
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** ** SMALL ENTITY **				
Foreign Priority claimed	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS
35 USC 119(a-d) conditions met	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		GERMANY	8
Verified and	LYNN ANNE BRISTOL			TOTAL CLAIMS
Acknowledged	Examiner's Signature	Initials		12
INDEPENDENT CLAIMS 2				
ADDRESS MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201 UNITED STATES				
TITLE Use of egfr transactivation inhibitors in human cancer				
FILING FEE RECEIVED 525	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees	
			<input type="checkbox"/> 1.16 Fees (Filing)	
			<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)	
			<input type="checkbox"/> 1.18 Fees (Issue)	
			<input type="checkbox"/> Other _____	
		<input type="checkbox"/> Credit		